Evidence map›Paper›PMID 42383558›Full record

ArticleSmall (Weinheim an der Bergstrasse, Germany)2026

Multifunctional Nanodiamond Conjugate With a Tumor-Specific EGFR-Targeting Peptide and Photoactivated CO Release for Improved Therapeutic Efficacy in Head and Neck Cancers.

Harsh Nitin Dongre, Elisabeth Mayerhoefer, Julia Puck, Himalaya Parajuli, Lorena Larios Salazar, Paul Johan Høl, Ridhima Das, Patrick Roth, Christian Arvei Moen, Ulrich Schatzschneider and 3 more

Abstract read
In one paragraph

Article in Small (Weinheim an der Bergstrasse, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Harsh Nitin DongreThe Gade Laboratory for Pathology, Department of Clinical Medicine, University of Bergen, Bergen, Norway.ORCID 0000-0003-4378-2869
Elisabeth MayerhoeferInstitute of Organic Chemistry, University of Stuttgart, Stuttgart, Germany.ORCID 0009-0005-4907-1891
Julia PuckInstitute of Organic Chemistry, Julius-Maximilians-Universität Würzburg, Würzburg, Germany.
Himalaya ParajuliThe Gade Laboratory for Pathology, Department of Clinical Medicine, University of Bergen, Bergen, Norway.ORCID 0000-0001-7185-0844
Lorena Larios SalazarThe Gade Laboratory for Pathology, Department of Clinical Medicine, University of Bergen, Bergen, Norway.
Paul Johan HølDepartment of Clinical Medicine, University of Bergen, Bergen, Norway.ORCID 0000-0002-4216-7891
Ridhima DasThe Gade Laboratory for Pathology, Department of Clinical Medicine, University of Bergen, Bergen, Norway.
Patrick RothInstitute of Inorganic Chemistry, Julius-Maximilians-Universität Würzburg, Würzburg, Germany.
Christian Arvei MoenDepartment of Urology, Haukeland University Hospital, Bergen, Norway.ORCID 0000-0002-8356-0526
Ulrich SchatzschneiderInstitute of Inorganic Chemistry, Julius-Maximilians-Universität Würzburg, Würzburg, Germany.ORCID 0000-0002-1960-1880
Line BjørgeCentre for Cancer Biomarkers, Faculty of Medicine, University of Bergen, Bergen, Norway.
Daniela Elena CosteaThe Gade Laboratory for Pathology, Department of Clinical Medicine, University of Bergen, Bergen, Norway.
Anke KruegerInstitute of Organic Chemistry, University of Stuttgart, Stuttgart, Germany.ORCID 0000-0003-3082-4935

Funding

Carl-Zeiss-Stiftung CZSCenterforQuantumPhotonicsCarl-Zeiss-Stiftung (P2021-00-019)Carl-Zeiss-Stiftung QPhotonFederal Ministry of Research, Technology and Space BMFTR 03ZU1110FEThe Research Council of Norway 22325University of Bergen, Norway and Norwegian Research Council's 349789West Norway Health Authority F-13105/2024
6 · The paper itself

Abstract

The targeted and stimuli-responsive delivery of drugs for the treatment of cancer using functionalized nanoparticles is a promising avenue for therapeutic applications. However, many of these conjugates are limited by either low biocompatibility, poor targeting efficiency or complex requirements for the response to stimuli. Here we report a highly efficient nanodiamond conjugate for the light induced delivery of carbon monoxide, a potent anti-tumor agent. Nanodiamond particles are well-known for their high biocompatibility, rich surface chemistry, and low cytotoxicity. Using co-functionalization with an EGFR-targeting peptide and a manganese carbonyl complex as PhotoCORM, the efficient delivery of CO to cancer cells is demonstrated with spatiotemporal resolution both in vitro and in vivo using blue-light photoactivation. In vitro experiments using head and neck cancer models show significant cancer-specific cytotoxicity only upon blue-light exposure, whereas limited toxicity was observed toward non-cancerous and pre-malignant cells. Further in vivo experiments demonstrate the significant suppression of tumor growth and lymph node metastasis in a head and neck cancer xenograft mouse model while maintaining excellent biocompatibility. This paves the way for the application of multifunctional, nanodiamond-based delivery tools in the stimuli responsive treatment of tumors.

Indexed as

ErbB ReceptorsHead and Neck NeoplasmsNanodiamondsPeptidesAnimalsCell Line, TumorHumansMiceErbB ReceptorsNanodiamondsPeptidescancer treatmentdiamond nanoparticlesnanocarbonphotoCORMstimuli‐responsive targeted drug deliverysurface chemistry

Identifiers

PMID42383558
PMCPMC13495914

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.